Minerva Neurosciences, Inc

Ticker NERV

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

11-50 Employees
Based in Waltham, Massachusetts

Minerva鈥檚 portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson鈥檚 disease. Minerva鈥檚 common stock is listed on the NASDAQ Global Market under the symbol 鈥淣ERV鈥�.

REPORT RATINGS

4.7 / 5.0 (115)

Minerva Neurosciences, Inc reports have an aggregate usefulness score of 4.7 based on 115 reviews.

Minerva Neurosciences, Inc